SCHEMBL4665825

SCHEMBL4665825

Cc1ccc(S(=O)(=O)N(OC=O)c2ccc(Nc3cc(-c4ccc(OCCN5CCN(C)CC5)cc4)ncn3)cc2)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABL1 P00519 4/20 0.40
BCR P11274 4/20 0.40
SRC P12931 7/20 0.39
YES1 P07947 1/20 0.39
FGFR1 P11362 2/20 0.39
BACE1 P56817 1/20 0.39
CXCR1 P25024 1/20 0.38
CYP3A4 P08684 2/20 0.36
FGFR3 P22607 1/20 0.36
MEN1 O00255 1/20 0.36
USP2 O75604 1/20 0.36
ALDH1A1 P00352 1/20 0.36
TP53 P04637 1/20 0.36
CYP1A2 P05177 1/20 0.36
GLA P06280 1/20 0.36
CYP2D6 P10635 1/20 0.36
CYP2C9 P11712 1/20 0.36
ALOX15 P16050 1/20 0.36
MAPK1 P28482 1/20 0.36
CYP2C19 P33261 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4663885 0.95 FGFR3 (0.41) ABL1BCRSRCYES1FGFR1
SCHEMBL4664290 0.94 ABL1 (0.43) ABL1BCRSRCFGFR1CXCR1
SCHEMBL4665779 0.90 CXCR1 (0.47) ABL1BCRSRCFGFR1BACE1
SCHEMBL4665647 0.89 ABL1 (0.40) ABL1BCRBACE1CYP3A4MEN1
SCHEMBL4665705 0.89 CYP3A4 (0.44) ABL1BCRCYP3A4FGFR3JAK2
SCHEMBL4667537 0.89 EGFR (0.41) ABL1BCRSRCFGFR1CXCR1
SCHEMBL4665855 0.88 EGFR (0.40) ABL1BCRBACE1CXCR1CYP3A4
SCHEMBL4664335 0.87 ABL1 (0.43) ABL1BCRSRCYES1FGFR1
SCHEMBL4664327 0.87 ABL1 (0.41) ABL1BCRSRCYES1FGFR1
SCHEMBL4667432 0.86 CYP3A4 (0.42) ABL1BCRSRCYES1FGFR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080242681-A1 N-4-(6-(Hetero)Aryl-Pyrimidin-4-Ylaminophenyl)-Benzenesulfonamides as Kinase Inhibitors ALTANA PHARMA AG (DE) 2008-10-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080242681-A1 N-4-(6-(Hetero)Aryl-Pyrimidin-4-Ylaminophenyl)-Benzenesulfonamides as Kinase Inhibitors MAP3K19, MAP3K6, MAP3K20 ABL1 24/4885BCR 402/4885SRC 213/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.